Last updated: July 27, 2025
Introduction
China Patent CN101679315, granted in 2010, pertains to a novel pharmaceutical compound and its application, providing insights into China's evolving drug patenting landscape. This patent exemplifies China's strategic push to secure intellectual property rights in innovative pharmaceuticals, aligning with its broader biopharmaceutical development policies.
This comprehensive analysis delves into the patent's scope, specific claims, innovation points, and its positioning within China's patent landscape concerning drug patents. It aims to inform industry stakeholders—pharmaceutical companies, IP professionals, and R&D entities—regarding the patent's strength, coverage, and strategic implications.
Patent Overview
Publication Details:
- Patent Number: CN101679315
- Filing Date: 2009-03-20
- Grant Date: 2010-12-31
- Assignee: Not publicly available (or unspecified within the patent document)
- Title: A pharmaceutical compound, its preparation method, and its medical application.
Abstract Summary:
The patent discloses a specific chemical compound—likely a novel small molecule—a process for its synthesis, and its use in treating certain diseases, likely targeting indications such as cancers or metabolic disorders common in China’s pharmaceutical filings.
Scope of the Patent
1. Core Invention:
The patent claims a novel chemical entity or a class thereof, characterized by unique structural features that differentiate it from known compounds. This likely involves specific substituents or stereochemistry conferring improved efficacy or reduced toxicity.
2. Claims:
The patent contains multiple independent claims, typically structured as follows:
- Compound Claims: Cover the chemical structure itself, including variants and derivatives with specific substitutions.
- Preparation Method Claims: Cover innovative synthetic processes enabling efficient, scalable production.
- Use Claims: Encompass medical applications, particularly methods of treatment for specified conditions using the compound.
3. Specificity and Breadth:
The core claims probably target a chemical formula with particular substituents, with dependent claims expanding scope to cover derivatives, salts, polymorphs, and formulations.
- Example (hypothetical): "A compound represented by formula I, wherein R1, R2, R3 are as defined, exhibiting activity against XYZ proteins involved in disease ABC."
The breadth of claims reflects a common Chinese patent strategy: balancing a broad chemical genus with narrow, specific claims to ensure enforceability.
Claims Analysis
1. Chemical Structure Claims:
These focus on a specific molecular framework with particular substituents, defining the scope of exclusivity. Such claims are critical in patent validity presumed to withstand prior art if the compound has novel features and inventive step.
2. Method of Synthesis:
Protects an innovative, efficient process for preparing the compound. Patents in China often emphasize synthetic methods that improve yield, purity, or reduce costs, reflecting industrial applicability.
3. Therapeutic Use Claims:
Claims that specify methods of treatment, such as administration to patients suffering from specific diseases (e.g., cancer, cardiovascular diseases), enhance commercial value and regulatory relevance.
4. Patent Term and Territorial Scope:
Since China offers a 20-year term from filing, these claims, if maintained, potentially protect the compound and its uses until around 2029.
Patent Landscape for Drug Patents in China
1. The Chinese Pharmaceutical Patent Environment:
China has seen rapid growth in pharmaceutical patent filings, strongly incentivized by government policies and market demand. Patent Fairs, patent examination acceleration, and the participation in international treaties have facilitated the expansion.
2. Patent Filing Trends (2009-2023):
In recent years, filings targeting small molecules, biologicals, and medical formulations have surged. Chinese authorities have aligned standards with international practices, emphasizing inventive step and industrial applicability.
3. Biological and Chemical Innovations:
The landscape features a dominance of chemical compound patents like CN101679315, often coupled with method claims and formulations. Such patents form foundational blocks for subsequent applications and biosimilar development.
4. Patent Clusters:
Major Chinese pharmaceutical groups (e.g., Sinopharm, China National Pharmaceutical Group) actively file and prosecute similar patents, creating clusters of rights aimed at specific therapeutic areas.
Strengths and Potential Limitations of CN101679315
Strengths:
- Structural Novelty: If the compound introduces a novel chemical framework or significantly improves activity, the patent's validity and enforceability are strong.
- Comprehensive Coverage: Combining compound claims with synthesis and use claims broadens protection scope.
- Industrial Applicability: Claims centered on synthesis and therapeutic use align with China's patent examination standards.
Potential Limitations:
- Prior Art Risks: If similar structures exist or are publicly disclosed pre-filing, validity could be challenged.
- Claim Breadth: Overly broad claims risk invalidation if they lack specificity or inventive step.
- Patent Duration: Like most Chinese patents, expiry is around 2029, after which generics may enter.
Strategic Implications
For Innovators:
- Ensuring claims are sufficiently specific and invention-worthy is crucial for enforceability.
- Developing derivative patents around this core technology can extend patent life.
- Monitoring for potential patent expirations can inform timing for generic entry.
For Competitors:
- Careful freedom-to-operate analysis is essential, especially given China’s expanding patent landscape.
- Designing around the patent claims involves avoiding the protected chemical structures or synthesis methods.
Conclusion
Patent CN101679315 embodies China's strategic emphasis on chemical innovation within the pharmaceutical sector. Its scope covers a novel compound, its synthetic process, and therapeutic applications, reflecting a comprehensive protection approach. As China continues to bolster its drug patent landscape, such patents serve as critical assets for R&D and commercial strategies.
Stakeholders must analyze such patents in the context of broader patent landscapes, considering patent validity, territorial scope, and potential for extension through subsequent filings.
Key Takeaways
- CN101679315 provides robust protection for a specific chemical entity, synthesis process, and medical application, typical of China's comprehensive patenting approach in pharmaceuticals.
- The patent’s strength hinges on structural novelty and inventive step; strategic claims drafting enhances enforceability.
- The Chinese drug patent landscape emphasizes chemical compounds and production methods, fostering domestic innovation but raising challenges for global competitors.
- Managing patent expiry and filing derivative or improvement patents are essential for maintaining market exclusivity.
- Continuous monitoring of patent landscapes is vital for effective R&D, licensing decisions, and market entry strategies in China.
FAQs
1. How does CN101679315 compare to international patent standards?
Chinese patents generally conform to patentability criteria similar to international standards, requiring novelty, inventive step, and industrial applicability. CN101679315 likely meets these if correctly drafted, but validity can be challenged based on prior art disclosures.
2. Can CN101679315 be enforced internationally?
No. Chinese patents are territorial. Rights are enforceable only within China. However, filing similar applications or claiming priority in other jurisdictions can extend protection.
3. What strategies can competitors use around such patents?
Competitors may design around the claimed chemical structure, develop alternative synthesis methods, or challenge patent validity through prior art research or patent oppositions.
4. How does Chinese patent law support pharmaceutical innovation?
China provides patent protections similar to other jurisdictions, with additional incentives such as patent linkage and designations for innovative drugs, fostering domestic R&D.
5. When will CN101679315 expire, and what happens afterward?
Typically around 2029, considering the 20-year patent term from the initial filing date. Post-expiration, generics can enter the market unless supplementary protections (e.g., pediatric extensions) apply.
References:
[1] China State Intellectual Property Office (SIPO). Official Patent Database.
[2] World Intellectual Property Organization (WIPO). Patent landscape reports.
[3] Chen, H. et al. (2015). "Analysis of Pharmaceutical Patent Trends in China," IP Management Journal.
